急性缺血性卒中取栓器械非劣效界值是否过低
该系统评价分析了7项卒中血管内治疗(EVT)器械非劣效试验(共1766例),发现试验所用非劣效界值(再灌注15%、10%、8%,功能独立15%)普遍高于专家确定的MCID(再灌注3.1%~5%,功能独立5%和1%~1.5%)及心脏试验界值(3.5%~4.4%)。用原始宽界值时7项试验均显示非劣效,但用专家MCID界值时仅再灌注4项、功能独立3项仍显示非劣效。
要点
- 卒中EVT器械试验的非劣效界值常高于专家MCID和心脏器械试验界值。
- 再灌注MCID为3.1%~5%,而试验界值为8%~15%。
- 功能独立MCID为5%和1%~1.5%,而试验界值为15%。
核心结论
- EVT器械试验所用非劣效界值经常超过卒中专家确定的MCID以及心脏器械试验所用界值。
- 需要采用合理充分的性能界值而非非劣效界值来优化卒中EVT试验设计的完整性和可行性。
研究设计与样本
- 系统检索鉴定所有卒中EVT非劣效设计或非劣效解读的对照试验、确定相同结局MCID的研究以及冠状动脉血运重建非劣效试验。
- 共纳入7项卒中EVT非劣效设计或非劣效解读的对照试验,合计1766例患者,比较了线圈取栓器、第一代和第二代支架取栓器及抽吸装置。
主要发现
- 6项试验主要结局为再灌注达标,非劣效界值分别为15%(3项)、10%(2项)和8%(1项)。
- 1项试验主要结局为功能独立,非劣效界值为15%。
- 一项卒中专家调查确定再灌注MCID为3.1%~5%,心脏试验所用非劣效界值为3.5%~4.4%。
- 两项卒中专家调查研究确定功能独立MCID分别为5%和1%~1.5%。
- 用最宽非劣效界值时全部7项试验均显示非劣效,但用专家衍生界值时仅再灌注4项、功能独立3项试验显示非劣效。
关键数值与推荐
- 再灌注专家MCID为3.1%~5%,卒中EVT试验界值为15%、10%、8%。
- 功能独立专家MCID为5%和1%~1.5%,卒中EVT试验界值为15%。
- 心脏试验非劣效界值为3.5%~4.4%。
临床怎么用
- 解读卒中EVT器械非劣效试验时需关注所用界值是否接近专家MCID,避免因宽界值高估非劣效结论。
局限性
- 原文未报告系统检索的具体数据库、检索时间范围及纳入研究的偏倚风险评估方法。
- 原文未报告专家MCID调查的具体样本量、调查对象特征及调查方法细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Novel endovascular thrombectomy (EVT) devices for acute ischemic stroke are often cleared by regulatory agencies on the basis of noninferiority trials. The relation between the noninferiority margins used in trials and the minimal clinically important differences (MCIDs) determined by experts have not been systematically investigated. Methods- Systematic searches were performed to identify (1) all noninferiority design or noninferiority-presented stroke-EVT trials for acute ischemic stroke, (2) all studies determining the MCIDs for the same outcomes, and (3) all noninferiority coronary revascularization trials. Stroke-EVT trial results were reanalyzed using the broad noninferiority margins originally used and narrower noninferiority margins derived from formal MCID studies. Results- We identified 7 noninferiority-designed or noninferiority-interpreted stroke-EVT controlled trials, enrolling 1766 patients, variously comparing coil retrievers, first- and second-generation stent retrievers, and aspiration devices. In 6 trials, the primary outcome was achievement of reperfusion, using noninferiority margins of 15% (3 trials), 10% (2 trials), and 8% (1 trial). In contrast, a stroke expert survey identified the MCID for reperfusion as 3.1% to 5%, and cardiac trials used noninferiority margins of 3.5% to 4.4%. In one stroke-EVT trial, the primary outcome was functional independence, using a noninferiority margin of 15%. However, 2 stroke expert survey studies identified MCIDs for functional independence as having lower values, 5% and 1% to 1.5%. For both reperfusion and functional independence outcomes, all 7 trials demonstrated noninferiority with the broadest noninferiority margin, but only 4 and 3 trials demonstrated noninferiority with actual expert-derived margins for reperfusion and functional independence, respectively. Conclusions- Noninferiority margins used in EVT device trials have regularly exceeded the MCIDs determined by stroke experts, as well as margins used for cardiac devices. New approaches, such as the use of reasonably adequate performance margins, rather than noninferiority margins, are needed to optimize stroke-EVT trial design integrity and trial performance feasibility.
引用
- Lin CJ, Saver JL. Noninferiority Margins in Trials of Thrombectomy Devices for Acute Ischemic Stroke: Is the Bar Being Set Too Low? Stroke. 2019. PMID: 31619155. doi:10.1161/STROKEAHA.119.026717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。